A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

NCT05073315 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

425

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Adalimumab
DRUG: ABP 501

Sponsor

Amgen